



TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

12.08.2023

To,

BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street, Mumbai — 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Submission of Un-Audited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th June , 2023.

Please find the enclosed herewith Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th June, 2023 along with Limited Review Report thereon approved by the Board of Directors of the Company at its Meeting held on Saturday, 12th August, 2023 at A 601, Floor No.6, Kailash Business Park, Veer Savarkar Marg, Vikroli - West, Mumbai — 400079 at 5.30 p.m., in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you.

For Tejnaksh Healthcare Limited

Dr. Ashish V. Rawandale
Managing Director
DIN:- 02005733



Limited Review Report on unaudited Standalone Financial Results of Tejnakh Healthcare Limited for the quarter ended 30 June 2023 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Tejnakh Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Tejnakh Healthcare Limited ("the Company") for the quarter ended June 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles



P.D.DALAL & Co.^{Regd.}

Chartered Accountants

generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.D.Dalal & Co.
Chartered Accountants
ICAI Firm Reg No.102047W

Aashish

(Aashish S. Kakaria)
Partner
Membership No.102915
UDIN: 23102915BGSKPJ9947



Mumbai
12th August, 2023



TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE, 2023

Amount Rs. in Lacs

Sl.No.	Particulars	Quarter Ended			Year Ended
		June 30, 2023	March 31, 2023	June 30, 2022	March 31, 2023
		(Unaudited)	(Refer Note 4)	(Unaudited)	(Audited)
1	REVENUE				
(a)	Revenue from operations (net)	191.81	165.45	185.77	733.51
(b)	Other income	7.32	10.11	4.35	23.56
	Total Revenue (I)	199.13	175.56	190.12	757.08
2	EXPENSES				
(a)	Cost of Materials Consumed	3.85	13.19	-	13.19
(b)	Purchases of stock-in-trade	20.20	2.95	16.57	57.08
(c)	Changes in inventories of Stock-in-Trade	(0.91)	26.07	2.68	16.52
(d)	Employee benefits expense	20.92	21.13	17.69	77.92
(e)	Finance costs	16.73	17.54	13.52	61.31
(f)	Depreciation and amortization expense	20.12	20.09	19.62	79.02
(g)	Other expenses	95.96	71.48	53.11	255.76
	Total Expenses (II)	176.88	172.45	123.20	560.80
3	Profit before tax (I) - (II)	22.25	3.11	66.92	196.28
4	Tax expense:				
(a)	Current tax	0.59	(5.19)	11.13	24.96
(b)	Adjustment of tax relating to earlier periods		8.78	-	8.78
(c)	Deferred tax	5.30	6.08	5.71	24.54
	Total Tax Expenses	5.89	9.67	16.84	58.28
5	Profit for the Period	16.37	(6.56)	50.08	137.99
6	OTHER COMPREHENSIVE INCOME				
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:				
	Actuarial gain / (loss) on liabilities	0.42	0.84	0.29	1.69
	Income tax effect	(0.11)	(0.21)	(0.07)	(0.43)
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:				
	Other Comprehensive income for the period, net of tax	0.32	0.63	0.21	1.27
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	16.68	(5.93)	50.29	139.26
7	Paid up Equity Share Capital (Face value Rs 5/- each.)	1,015.68	1,015.68	1,015.68	1,015.68
8	Basic and Diluted earnings per share (INR)	0.08	(0.03)	0.25	0.68





TEJNAKSH HEALTHCARE LIMITED

Regd. Add.: A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

Notes:

- 1) The Statement of unaudited standalone financial results ('the Statement') of Tejnaksh Healthcare Limited ('the Company') for the quarter ended June 30, 2023 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on August 12, 2023. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3) The Company's operating segment is 'Medical and Healthcare Services'. Since the Company has a single operating segment the disclosure pertaining to segments is not applicable.
- 4) The figures of the last quarter are the balancing figures between audited figures in respect of full previous financial year and the published year to date figures upto the end of the third quarter of the previous financial year.
- 5) The figures for the corresponding previous periods have been regrouped / reclassified wherever necessary, to make them comparable.
- 6) The company has considered the proposal of sub-division of equity shares having face value of Rs.10/- each fully paid up into equity shares having face value of Rs 5/- each fully paid up. On 24th June 2023 said proposal was approved by the shareholders at the Extra Ordinary general Meeting with a record date as 19th July 2023. In Accordance with Ind As 33, (Earning Per Share), the EPS in point 8 of the statement above has been retrospectively adjusted.

For and on behalf of board of Directors

Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)

Managing Director

DIN: 02005733



Mumbai

August 12, 2023

Limited Review Report on unaudited consolidated financial results of Tejnakh Healthcare Limited for the quarter ended 30 June 2023 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Tejnakh Healthcare Limited**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Tejnakh Healthcare Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes results of the Holding Company- Tejnakh Healthcare Limited and subsidiary Company - TejVedaant Healthcare Private Limited.

5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its subsidiary which have been approved and furnished to us by the management. Our conclusion on the Statement is not modified in respect of the above matter.

6. Attention is drawn to the fact that the figures for the three months ended 31 March 2023 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The



figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

7. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.D.Dalal & Co.
Chartered Accountants
ICAI Firm Reg No.102047W

Aashish

(Aashish S. Kakaria)

Partner

Membership No.102915

UDIN: 23102915BGSKPK9188



Mumbai

12th August, 2023



TEJNAKSH HEALTHCARE LIMITED

Regd. Add.: A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE, 2023

Amount Rs. in Lacs

Sl.No.	Particulars	Quarter Ended			Year Ended
		June 30,2023	March 31,2023	June 30,2022	March 31,2023
		(Unaudited)	(Refer Note 4)	(Unaudited)	(Audited)
1	REVENUE				
(a)	Revenue from operations (net)	302.51	265.21	288.48	1,172.70
(b)	Other income	8.04	14.23	4.35	30.72
	Total Revenue (I)	310.55	279.44	292.83	1,203.42
2	EXPENSES				
(a)	Cost of Materials Consumed	3.85	13.19	-	13.19
(b)	Purchases of stock-in-trade	38.18	16.42	33.38	121.06
(c)	Changes in inventories of Stock-in-Trade	(1.72)	22.57	(1.05)	6.88
(d)	Employee benefits expense	35.97	36.92	32.20	137.22
(e)	Finance costs	15.76	17.03	13.52	60.80
(f)	Depreciation and amortization expense	22.51	22.39	21.66	87.38
(g)	Other expenses	174.52	139.60	115.56	525.64
	Total Expenses (II)	289.07	268.13	215.27	952.17
3	Profit before tax (I) - (II)	21.48	11.31	77.55	251.25
4	Tax expense:				
(a)	Current tax	0.59	(3.39)	13.82	38.49
(b)	Adjustment of tax relating to earlier periods	-	8.78	-	8.78
(c)	Deferred tax	5.11	6.35	5.69	24.85
	Total Tax Expenses	5.69	11.73	19.52	72.12
5	Profit for the year	15.79	(0.42)	58.04	179.13
6	OTHER COMPREHENSIVE INCOME				
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:				
	Actuarial gain / (loss) on liabilities	0.81	0.85	0.80	3.25
	Income tax effect	(0.20)	(0.21)	(0.20)	(0.82)
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:				
	Other Comprehensive income for the year, net of tax	0.61	0.63	0.60	2.43
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	16.40	0.21	58.63	181.56
7	Profit for the year attributable to:				
	Equity holders of the parent	15.93	(2.54)	56.05	168.27
	Non-controlling interests	(0.14)	2.12	1.99	10.87

Sansudha





TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai-400079

CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com

Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

8	Other comprehensive income for the period attributable to:				
	Equity holders of the parent				
	Non-controlling interests	0.54	1.21	0.50	2.72
		0.07	(0.58)	0.10	(0.29)
9	Total comprehensive income for the period attributable to:				
	Equity holders of the parent				
	Non-controlling interests	16.47	(1.32)	56.55	170.99
		(0.07)	1.54	2.09	10.58
10	Paid up Equity Share Capital (Face value Rs 5/- each.)	1,015.70	1,015.70	1,015.70	1,015.70
11	Basic and Diluted earnings per share (INR)	0.08	(0.01)	0.28	0.83

Notes:

- 1) The Statement of unaudited consolidated financial results ('the Statement') of Tejnaksh Healthcare Limited (the 'Parent'/'Group') and its subsidiaries (together referred to as the 'Group') for the quarter ended June 30, 2023 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on August 12, 2023. The Statutory Auditors of the Group have carried out a Limited Review of the aforesaid results.
- 2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3) The Group's operating segment is 'Medical and Healthcare Services'. Since the Company has a single operating segment the disclosure pertaining to segments is not applicable.
- 4) The figures of the last quarter are the balancing figures between audited figures in respect of full previous financial year and the published year to date figures upto the end of the third quarter of the previous financial year.
- 5) The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.
- 6) The holding company has considered the proposal of sub-division of equity shares having face value of Rs.10/- each fully paid up into equity shares having face value of Rs 5/- each fully paid up. On 24th June 2023 said proposal was approved by the shareholders at the Extra Ordinary general Meeting with a record date as 19th July 2023.
In Accordance with Ind As 33, (Earning Per Share), the EPS in point 11 of the statement above has been retrospectively adjusted.

For and on behalf of board of Directors

Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)

Managing Director

DIN: 02005733



Mumbai

August 12, 2023